Vimarsana
Biggest News Aggregation in the World

Study Drugs News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Study Drugs. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Study Drugs Today - Breaking & Trending Today

Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial | Anticoagulation | JAMA - Vimarsana News

Effect of Intermediate-Dose vs Standard-Dose Prophylactic Anticoagulation on Thrombotic Events, Extracorporeal Membrane Oxygenation Treatment, or Mortality Among Patients With COVID-19 Admitted to the Intensive Care Unit: The INSPIRATION Randomized Clinical Trial | Anticoagulation | JAMA

This randomized trial compares the effect of intermediate-dose vs standard prophylactic enoxaparin on a composite outcome of acute venous thromboembolism (VTE),

[STUDY] Most Americans Think Inhaling Marijuana Smoke is Safer Than Cigarettes; Health Experts Now Concerned - Vimarsana News

[STUDY] Most Americans Think Inhaling Marijuana Smoke is Safer Than Cigarettes; Health Experts Now Concerned

Most Americans think inhaling marijuana smoke is safer than cigarettes. Here's what the new study revealed.

Source: hngn.com
Global Pancreatic Cancer Competitive Landscape Report 2023: Comprehensive Insights about 250+ Companies and 300+ Drugs - Vimarsana News

Global Pancreatic Cancer Competitive Landscape Report 2023: Comprehensive Insights about 250+ Companies and 300+ Drugs

/PRNewswire/ -- The "Pancreatic Cancer - Competitive landscape, 2023" report has been added to ResearchAndMarkets.com's offering. This "Pancreatic Cancer-...

AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center - Vimarsana News

AIM ImmunoTech Enters into Pancreatic Cancer Clinical Research Agreements with AstraZeneca and Erasmus Medical Center

17.01.2023 - Research collaboration will evaluate the potential of AIM’s Ampligen (rintatolimod) in combination with AstraZeneca’s Imfinzi (durvalumab) for the treatment of pancreatic cancerOCALA, Fla., Jan. 17, 2023 (GLOBE NEWSWIRE) - AIM ImmunoTech Inc. ... Seite 1

AIM ImmunoTech Inks Pancreatic Cancer Clinical Research Deals With AstraZeneca, Erasmus - Vimarsana News

AIM ImmunoTech Inks Pancreatic Cancer Clinical Research Deals With AstraZeneca, Erasmus

LONDON (dpa-AFX) - Immuno-pharma company AIM ImmunoTech Inc. (AIM) announced Tuesday it has entered into an external sponsored collaborative clinical research agreement with Netherland-based Erasmus